Diagnostic value of human epididymis protein 4 compared with mesothelin for ovarian cancer: A systematic review and meta-analysis

Asian Pacific Journal of Cancer Prevention

Volumn 13, Issue 11, 2012, Pages 5427-5432

  Lin, Jia Ying ^a   Qin, Jin Bao ^b   Li , Xiao Yan ^c   Dong, Ping ^a   Yin, Bing De ^d  

^a Department of Otolaryngology Head and Neck Surgery ^*  (China)

^b SHANGHAI SECOND MEDICAL UNIVERSITY   (China)

^c SHANGHAI JIAO TONG UNIVERSITY   (China)

^d SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

Author keywords

Analysis; HE4; Mesothelin; Meta; Ovarian carcinoma

Indexed keywords

EID: 84874064561     PISSN: 15137368     EISSN: 2476762X     Source Type: Journal    
DOI: 10.7314/APJCP.2012.13.11.5427     Document Type: Article

References (33)

1. Abdel-Azeez HA, Labib HA, Sharaf SM, Refaie AN (2010). He4 and mesothelin: Novel biomarkers of ovarian carcinoma in patients with pelvic masses. Asian Pac J Cancer Prev, 11, 111-6.
2. Badgwell D, Lu Z, Cole L, et al (2007). Urinary mesothelin provides greater sensitivity for early stage ovarian cancer than serum mesothelin, urinary hcg free beta subunit and urinary hcg beta core fragment. Gynecol Oncol, 106, 490-7.
3. Bast RC, Jr (2004). Early detection of ovarian cancer: New technologies in pursuit of a disease that is neither common nor rare. Trans Am Clin Climatol Assoc, 115, 233-47; discussion 47-8.
4. Chang K, Pastan I (1996). Molecular cloning of mesothelin, a differentiation antigen present on mesothelium, mesotheliomas, and ovarian cancers. P Natl Acad Sci USA, 93, 136-40.
5. Chang XH, Ye X, Dong L, et al (2011). Human epididymis protein 4 (he4) as a serum tumor biomarker in patients with ovarian carcinoma. Int J Gynecol Cancer, 21, 852-8.
6. Deeks JJ (2001). Systematic reviews in health care: Systematic reviews of evaluations of diagnostic and screening tests. BMJ, 323, 157-62.
7. DerSimonian R, Laird N (1986). Meta-analysis in clinical trials. Controlled Clin Trials, 7, 177-88.
8. Dinnes J, Deeks J, Kirby J, Roderick P (2005). A methodological review of how heterogeneity has been examined in systematic reviews of diagnostic test accuracy. Health Technol Asses, 9, 1-6.
9. Drapkin R, von Horsten HH, Lin Y, et al (2005). Human epididymis protein 4 (he4) is a secreted glycoprotein that is overexpressed by serous and endometrioid ovarian carcinomas. Cancer Res, 65, 2162-9.
10. Glas AS, Lijmer JG, Prins MH, Bonsel GJ, Bossuyt PM (2003). The diagnostic odds ratio: A single indicator of test performance. J Clin Epidemiol, 56, 1129-35.
11. Hassan R, Remaley AT, Sampson ML, et al (2006). Detection and quantitation of serum mesothelin, a tumor marker for patients with mesothelioma and ovarian cancer. Clin Cancer Res, 12, 447-53.
12. Hellstrom I, Raycraft J, Hayden-Ledbetter M, et al (2003). The he4 (wfdc2) protein is a biomarker for ovarian carcinoma. Cancer Res, 63, 3695-700.
13. Holcomb K, Vucetic Z, Miller C, Knapp RC (2011). Human epididymis protein 4 offers superior specificity in the differentiation of benign and malignant adnexal masses in premenopausal women. Am J Obstet Gynecol, 205, 358.e1-6.
14. Huedo-Medina TB, Sanchez-Meca J, Marin-Martinez F, Botella J (2006). Assessing heterogeneity in meta-analysis: Q statistic or i2 index? Psychol Methods, 11, 193-206.
15. Huhtinen K, Suvitie P, Hiissa J, et al (2009). Serum he4 concentration differentiates malignant ovarian tumours from ovarian endometriotic cysts. Brit J Cancer, 100, 1315-9.
16. Jacob F, Meier M, Caduff R, et al (2011). No benefit from combining he4 and ca125 as ovarian tumor markers in a clinical setting. Gynecol Oncol, 121, 487-91.
17. Jacobs I, Bast RC, Jr (1989). The ca 125 tumour-associated antigen: A review of the literature. Hum Reprod, 4, 1-12.
18. Jaeschke R, Guyatt G, Sackett DL (1994). Users guides to the medical literature .3. How to use an article about a diagnostic-test .A. Are the results of the study valid. Jama-J Am Med Assoc, 271, 389-91.
19. Jemal A, Siegel R, Ward E, et al (2006). Cancer statistics, 2006. CA: Cancer J Clin, 56, 106-30.
20. McIntosh MW, Drescher C, Karlan B, et al (2004). Combining ca 125 and smr serum markers for diagnosis and early detection of ovarian carcinoma. Gynecol Oncol, 95, 9-15.
21. Medeiros LR, Rosa DD, da Rosa MI, Bozzetti MC (2009). Accuracy of ca 125 in the diagnosis of ovarian tumors: A quantitative systematic review. Eur J Obstet Gynecol Reprod Biol, 142, 99-105.
22. Montagnana M, Lippi G, Ruzzenente O, et al (2009). The utility of serum human epididymis protein 4 (he4) in patients with a pelvic mass. J Clin Lab Anal, 23, 331-5.
23. Moore RG, Brown AK, Miller MC, et al (2008). The use of multiple novel tumor biomarkers for the detection of ovarian carcinoma in patients with a pelvic mass. Gynecol Oncol, 108, 402-8.
24. Nolen B, Velikokhatnaya L, Marrangoni A, et al (2010). Serum biomarker panels for the discrimination of benign from malignant cases in patients with an adnexal mass. Gynecol Oncol, 117, 440-5.
25. Palmer C, Duan XB, Hawley S, et al (2008). Systematic evaluation of candidate blood markers for detecting ovarian cancer. Plos One, 3, e2633.
26. Park Y, Kim Y, Lee EY, Lee JH, Kim HS (2012). Reference ranges for he4 and ca125 in a large asian population by automated assays and diagnostic performances for ovarian cancer. Int J Cancer, 130, 1136-44.
27. Salceda S, Tang T, Kmet M, et al (2005). The immunomodulatory protein b7-h4 is overexpressed in breast and ovarian cancers and promotes epithelial cell transformation. Exp Cell Res, 306, 128-41.
28. Scholler N, Fu N, Yang Y, et al (1999). Soluble member(s) of the mesothelin/megakaryocyte potentiating factor family are detectable in sera from patients with ovarian carcinoma. P Natl Acad Sci USA, 96, 11531-6.
29. Scholler N, Lowe KA, Bergan LA, et al (2008). Use of yeastsecreted in vivo biotinylated recombinant antibodies (biobodies) in bead-based elisa. Clin Cancer Res, 14, 2647-55.
30. Shah CA, Lowe KA, Paley P, et al (2009). Influence of ovarian cancer risk status on the diagnostic performance of the serum biomarkers mesothelin, he4, and ca125. Cancer Epidem Biomar, 18, 1365-72.
31. Van Gorp T, Cadron I, Despierre E, et al (2011). He4 and ca125 as a diagnostic test in ovarian cancer: Prospective validation of the risk of ovarian malignancy algorithm. Brit J Cancer, 104, 863-70.
32. Whiting P, Rutjes AW, Reitsma JB, Bossuyt PM, Kleijnen J(2003). The development of quadas: A tool for the quality assessment of studies of diagnostic accuracy included in systematic reviews. BMC Med Res Methodol, 3, 25.
33. Williams TI, Toups KL, Saggese DA, et al (2007). Epithelial ovarian cancer: Disease etiology, treatment, detection, and investigational gene, metabolite, and protein biomarkers. J Proteome Res, 6, 2936-62.